m6A-centered Disease Response Information
General Information of the Disease (ID: M6ADIS0047)
| Name |
Lymphoma
|
||||
|---|---|---|---|---|---|
| ICD |
ICD-11: 2A70
|
||||
Full List of Target Gene(s) of This m6A-centered Disease Response
microRNA 211 (MIR211)
| In total 1 item(s) under this target gene | ||||
| Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [1] | |||
| Response Summary | microRNA 211 (MIR211) is a novel tumor suppressor in T-cell lymphoblastic lymphoma,it regulated by METTL14. Targeting of miR-211/TCF12 axis is a potential treatment for T-cell lymphoblastic lymphoma patients. | |||
| Responsed Disease | Lymphoma [ICD-11: 2A70] | |||
| Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
| Target Regulation | Up regulation | |||
| In-vitro Model | CCRF-CEM | T acute lymphoblastic leukemia | Homo sapiens | CVCL_0207 |
| H9 | Sezary syndrome | Homo sapiens | CVCL_1240 | |
| Jurkat | T acute lymphoblastic leukemia | Homo sapiens | CVCL_0065 | |
| SUP-T1 | Childhood T lymphoblastic lymphoma | Homo sapiens | CVCL_1714 | |
| In-vivo Model | Subcutaneously injected with 5 × 106 Jurkat cells and fed under Specific Pathogen Free (SPF) conditions. One week later, tumor mass was injected once a week with Agomir NC, Agomir-211, Antagomir NC and Antagomir 211, respectively, for three weeks. | |||